ClinicaliQ Trial Snapshot
- A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF) — Recruiting • Phase III • Cardiology / Cardiovascular • NCT06024746.
- What is being tested: The combination of finerenone (a non-steroidal mineralocorticoid receptor antagonist) plus empagliflozin (an SGLT2 inhibitor) versus standard care in hospitalised heart failure patients, evaluating both efficacy and safety outcomes.
- Patient eligibility overview: The trial focuses on patients requiring hospitalisation for acute heart failure, representing a high-risk population with significant morbidity and mortality requiring urgent therapeutic intervention.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
Eligibility Snapshot
- : * Provide electronic or written informed consent, either personally or through a legally authorized representative, as permitted by local regulations * Age ≥18 years or legal age of majority if >18 years in the participant's country of residence * Current hospitalization or recently discharged with the primary diagnosis of heart failure * Heart failure signs and symptoms at the time of hospital admission * Elevated N-terminal pro B-type natriuretic peptide (NTproBNP) ≥500 pg/mL or B-type natriuretic peptide (BNP) ≥125 pg/mL according to the local lab for patients in sinus rhythm; or elevated NTproBNP ≥1500 pg/mL or BNP ≥375 pg/mL for patients with atrial fibrillation (AF), measured during the current hospitalization or in the 72 hours prior to hospital admission * Fulfillment of protocol defined stabilization criteria (if randomized during hospitalization) * Treatment during the index hospitalization with at least 1 intravenous dose of a loop diuretic (e.g., furosemide, torsemide, bumetanide). * Negative pregnancy test and agreement to use adequate contraception during trial (female participants only)
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.